Black Forest Biologicals, a biotech startup, has a promising Alzheimer's drug candidate Compound SLT-88 entering Phase I trials this year. SLT-88 is the only product formed by the reaction of two precursor compounds A and B, both of which are quite expensive. The chief medicinal chemist of Black Forest is trying out different reaction conditions to minimize the cost of manufacturing SLT-88.
In the table below are listed the initial and final amounts of A and B used under two different trial conditions, and also the actual amount of SLT-88 recovered in each case. Complete the table by calculating the theoretical yield of SLT-88 and the percent yield of SLT-88. Round your amounts to the nearest milligram and your percentages to the nearest whole percent.
Trial
amount of
A
amount of
B
yield of SLT-88
initial
final
initial
final
theoretical
actual
%
1
350.mg
0mg
950.mg
589.mg
626.mg
%
2
300.mg
0mg
700.mg
518.mg
241.mg
%
Black Forest Biologicals, a biotech startup, has a promising Alzheimer's drug candidate Compound SLT-88 entering Phase I trials this year. SLT-88 is the only product formed by the reaction of two precursor compounds A and B, both of which are quite expensive. The chief medicinal chemist of Black Forest is trying out different reaction conditions to minimize the cost of manufacturing SLT-88.
In the table below are listed the initial and final amounts of A and B used under two different trial conditions, and also the actual amount of SLT-88 recovered in each case. Complete the table by calculating the theoretical yield of SLT-88 and the percent yield of SLT-88. Round your amounts to the nearest milligram and your percentages to the nearest whole percent.
Trial amount of A amount of B yield of SLT-88 initial final initial final theoretical actual % 1 350.mg 0mg 950.mg 589.mg 626.mg % 2 300.mg 0mg 700.mg 518.mg 241.mg %